How Many Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s Analysts Are Bearish?

September 16, 2018 - By Jeanette Kaplan

Investors sentiment increased to 1.53 in 2018 Q2. Its up 0.57, from 0.96 in 2018Q1. It increased, as 10 investors sold Vanda Pharmaceuticals Inc. shares while 33 reduced holdings. 18 funds opened positions while 48 raised stakes. 47.64 million shares or 3.78% more from 45.90 million shares in 2018Q1 were reported.
5,000 are owned by North Star Invest Management. First Manhattan accumulated 956,866 shares or 0.11% of the stock. Jacobs Levy Equity owns 41,300 shares. 223,574 are owned by Pnc Fincl Serv Grp Inc Inc. Goldman Sachs Grp Inc Inc invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, Foundry Prtnrs Ltd Liability Company has 0.04% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). National Bank Of Montreal Can invested in 0% or 77,349 shares. Virginia Retirement Et Al reported 39,600 shares. Voya Inv Ltd Liability Corporation has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Clarivest Asset Management Limited Liability holds 40,678 shares. Moreover, Kistler has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Cadence Management Ltd Liability Com reported 146,019 shares. Prudential Financial Inc holds 830,239 shares or 0.02% of its portfolio. Citadel Advisors reported 141,320 shares stake. Millennium Management Limited Liability reported 0.01% stake.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 3 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Vanda Pharmaceuticals had 3 analyst reports since May 23, 2018 according to SRatingsIntel. Below is a list of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings and price target changes.

14/09/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $30 Initiates Coverage On
23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $26 Initiates Coverage On
23/05/2018 Broker: Citigroup Rating: Buy Initiates Coverage On

The stock increased 7.57% or $1.4 during the last trading session, reaching $19.9. About 1.06M shares traded or 109.34% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 6.96% since September 16, 2017 and is uptrending. It has underperformed by 8.66% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.04 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 737.04 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by: Seekingalpha.com, which released: “HETLIOZ driving study demonstrates no impairment in next morning performance” on September 13, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on August 23, 2018 is yet another important article.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.